The Business Of Biotech Podcast
-
Obesity Tx End-Around With Skye Bioscience's Punit Dhillon
10/20/2024
While the trend toward CB1 inhibition for obesity took a small hit with the release of Novo Nordisk's small molecule oral cannabinoid receptor (CB1) inverse agonist monlunabant last month, Skye Bioscience Chairman and CEO Punit Dhillon is shaking it off. He's confident that his company's antibody-based approach to CB1 inhibition will make a moot point of the neuropsychiatric side effects that put a damper on Novo's data. On this episode of the Business of Biotech, we're digging into the uber-hot business of weight loss therapeutics.
-
Biotech C-Suite Construction With Allan Shaw
10/13/2024
Allan Shaw is back with us this week to dig into the complexities of strategic hiring in biotech. If you're growing a biotech in these volatile times, this episode of the Business of Biotech offers veteran insight you won't want to miss.
-
The Peptide Promise With NervGen's Mike Kelly
10/6/2024
Mike Kelly faced a self-reckoning before he took the job as CEO at NervGen Pharma, a company developing peptide therapeutics targeted specifically at central nervous system repair. The veteran of life sciences business development knew the ropes of the biotech C-suite. He’d been a CEO twice before. He knew how to launch drugs. He even knew how to sell them. On this episode of the Business of Biotech, we learn how Kelly reconciled that truth, and how NervGen is now leading the way for peptide therapeutics in spinal cord injury and beyond.
-
Biotech Course Correction With Treehill Partners' Ali Pashazadeh
9/29/2024
It wouldn't be accurate to say that surgeon-turned-healthcare investment banker and consultant Dr. Ali Pashazadeh traded his scalpels for spreadsheets. In fact, he still wields a scalpel quite frequently, and on this episode of the Business of Biotech podcast, he offers a fantastic reason why.
-
Embracing Biotech Chaos With Memo's Erik van den Berg
9/8/2024
Erik van den Berg is CEO and board member at Memo Therapeutics, and he's a student of biotech chaos. In fact, he's been embracing it with intention for the past 30 years. On this episode of the Business of Biotech, he walks us through the management of that chaos in specific detail.
-
Pivoting To RNA With Circio's Dr. Erik Digman Wiklund
9/1/2024
This week, it’s another “Business of Biotech-meets-Business-of-RNA” takeover with Circio CEO Erik Digman Wiklund, Ph.D. and guest co-host Anna Rose Welch of Advancing RNA. While Circio’s legacy is in cancer immunology (it still boasts a cancer vaccine candidate targeting KRAS driver mutations), the company made a bold pivot, of sorts, when it committed headlong to the circular RNA future. Now, it’s in the throes of fine-tuning a platform for the development of novel circRNA medicines for rare disease, vaccines, and cancer.
-
mRNA Upstarts With Radar Therapeutics' Sophia Lugo and Eerik Kaseniit, Ph.D.
8/25/2024
Guest co-host Anna Rose Welch of Advancing RNA fame joins us on this week’s Business of Biotech podcast for a conversation with the leaders of RNA upstart Radar Therapeutics. The company’s co-founders, Eerik Kaseniit, Ph.D. (CSO & President) and Sophia Lugo (CEO), are making waves in the mRNA therapeutics space on the heels of the invention of a precision-expressed mRNA technology that laid bare the path to Radar’s inception.
-
Steering Through Setbacks with AVEO Oncology's Michael Bailey
8/18/2024
For all the drug commercialization successes he's played a leading hand in during his tenures at GSK, Genentech, and ImClone — Androderm, Augmentin, necitumumab, and Erbitux among them — Michael Bailey concedes that he's likely better known for his failures. After hearing his stories on this episode of the Business of Biotech, I tend to disagree.
-
Leading From Within with ISCT & Kiji's Miguel Forte, M.D.
8/11/2024
He's been a big pharma executive. He's a multi-time biotech founder and current biotech CEO. He was once a regulator. He's a physician. He serves on multiple boards. And as of this summer, he's president of one of the most influential global organizations dedicated to the advance of cell and gene therapies (ISCT), and an executive member of another (ARM). Miguel Forte, M.D. simply can't stop finding places to apply his talents and energy to influence the advanced therapies landscape.
-
Expanding The Proteome with ProFound's John Lepore, M.D.
7/28/2024
Flagship Pioneering’s ProFound Therapeutics is on to something, and it could be something big. It began with a simple question: What if more RNAs were being translated into proteins? Answering that question took ProFound deep into the translatome.